# A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

> **NCT04680052** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Incyte Corporation** · enrollment: 654 (actual)

## Conditions studied

- Follicular Lymphoma
- Marginal Zone Lymphoma

## Interventions

- **DRUG:** tafasitamab
- **DRUG:** rituximab
- **DRUG:** lenalidomide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT04680052
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-15
- **Primary completion:** 2024-02-23
- **Final completion:** 2028-08-09
- **Target enrollment:** 654 (ACTUAL)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04680052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04680052, "A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04680052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*